and umbilical cord blood (n 5 48). Seventy-six percent received myeloablative conditioning. Scores were distributed as follows: HCT-CI 5 0 (n 5 185), 1-2 (n 5 33) and 3+ (n 5 34). Median follow-up was 343 days (range 110-624). The 1 year cumulative incidence of NRM increased (12%, 16% and 32%, respectively; p 5 0.02) and OS decreased (83%, 62% and 60%, respectively; p 5 0.01) with increasing HCT-CI scores. A multivariate analysis evaluating the effect of HCT-CI on NRM showed that those with scores of 1-2 and 3+ had a relative risk of death of 1.6 (95%CI 0.6-4.2, p 5 0.37) and 5.3 (95%CI 1.9-14.6, p\0.01) when compared to those with a score of zero. Similarly, when evaluating OS, those with scores of 1-2 and 3+ had a relative risk of death of 2.5 (95%CI 1.2-5.1, p 5 0.01) and 4.0 (95%CI 1.7-9.0, p\0.01), respectively. Other factors that had a significant impact on NRM and OS include donor type and conditioning intensity. HCT-CI score appears to predict NRM and OS in pediatric patients undergoing HCT and may be a useful tool to assess risk, guide counseling in the pre-transplant setting and devise innovative therapies for the highest risk group.
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CORRECTION OF IMMUNE DEFECT, EXCELLENT SURVIVAL, AND LONG-TERM DONOR CHIMERISM IN CHILDREN WITH CHRONIC GRANULOMA-TOUS DISEASE AFTER MYELOABLATIVE TRANSPLANTATION ACROSS DO-NOR AND GRAFT SOURCES Tewari, P., Martin, P.L., Parikh, S.H., Szabolcs, P., Page, K.M., Driscoll, T.A., Kurtzberg, J., Prasad, V.K. Duke University Medical Center, Durham, NC Background: Allogeneic hematopoietic stem cell transplantation (HSCT) is curative in chronic granulomatous disease (CGD) but access to HSCT is limited by donor availability and preparative regimen able to induce durable donor chimerism. Methods: Ten children (one female, 6 Caucasian, 3 CMV seropositive) with clinically severe CGD (x-linked, n 5 6; autosomal, n 5 4) received myeloablative HSCT at our center between 1997 and 2009. Seven were previously treated with interferon. Pretransplant morbidities included a median of 3 (range, 2-9) serious bacterial/fungal infections, including one invasive pulmonary aspergilosis treated with antifungals for .1 year, and one primary graft failure (GF) after reduced intensity HSCT at another institution. At transplant, median age and weight were 10.25 years (range, 0.7-11.7) and 19.6 kg (range, 9.6-60) . Graft sources were matched sibling bone marrow (SibBM) in 5, unrelated cord blood (UCB) in 4 and sibling cord blood (SibCB) in 1 patient. SibBM and SibCB donors were 6/6 HLA matched. UCB units were 4/ 6 (n 5 1) or 5/6 (n 5 3) and contained a median of 3.8Â10^7 precyropreservation nucleated cells/kg. SibBM patients received Busulfan (Bu) and Cyclophosphamide (Cy) 6 ATG. Primary GF following Bu/Cy/ATG in the first UCB recipient led to the use of Fludarabine(Flu)/Bu/Cy/ATG in subsequent CB patients. Five patients received irradiated granulocyte transfusions (4 from GCSF mobilized family donors; one from Red Cross) until engraftment.
Results: Currently, all patients are alive, free of infections, doing well (Lansky, 70-100) and have normal respiratory bursts at a median follow-up of 56 (range, 3-144) months. Two UCB recipients developed primary GF but were successfully retransplanted with a second UCB unit after additional conditioning with Flu/Cy with TBI (200 cGy) or Campath. One patient developed interstitial pneumonitis post transplant. Chimerism was all donor in 8 and 94% and 74% in the other two patients. Grade III/IV acute GvHD developed in two and extensive chronic GvHD in 1 patient. Conclusions: Myeloablative allogeneic HSCT with a HLAmatched sibling or UCB donor corrects neutrophil dysfunction, results in durable high-level chimerism, and excellent survival with minimal GvHD. Durable engraftment was acheived after second transplant in patients who had GF after the first transplants. Patients transplanted with UCB had equivalent outcomes to those with HLA-matched siblings. Objectives: We set out to determine if the tempo and quality of immune recovery during the first year after UCBT can predict survival. Methods: A pediatric cohort (n 5 93) was transplanted between July 2005 and September 2008 at a single center. All studied patients engrafted fully following myeloablative conditioning and a single CB graft. Immune reconstitution was monitored longitudinally by a uniform 4 color FACS panel to enumerate B and NK cells along with DC and T cell subsets. Two sided t-test was employed in univariate analyses to test for differences between the mean values generated from all time points (n 5 432) between those alive and those who eventually died. Logistic regression models were created comparing patients above and below the median values obtained during the first 365 days post-UCBT using forward selection method. Results: 63 of 93 children were transplanted for non-malignant diseases and 19 of them were minority. The median age was 2.1 years (range 0.1 to 18), 58%were male, 36% were 4/6, 41% were 5/6, and 23% were 6/6 HLA match. Overall, 67 patients (72%) are alive. Univariate analysis demonstrated that those who never died had significantly more circulating CD4+, CD8 + T cells, B cells, Tregs, RTE, and plasmacytoid DC. In this cohort where all studied patients have already engrafted and where death was infrequent, gender, race, CMV serology, TNC, CD34+ cell dose, TBI, acute GVHD 2-4 or 3-4 had no impact on overall survival. 2.8* (1.3-6.0) 5.3** (1.9-14.6) *P-value \0.05, ** P-value \0.01; #Multivariate analysis adjusted for age, conditioning intensity and donor type.
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However, malignant disease remained a predictor for lower OS. .3 at 95% CI, p 5 0.007). In multivariate analysis of OS modeling, comparing mean values acquired only between day 0 to Day 365, more accelerated thymic recovery in the first year (.9% of circulating T cells with a RTE phenotype [CD62L+/ CD45RA+]), was the only immune parameter that was associated with a reduced risk of death at any time point, HR 0.20 (0.07-0.60, 95%CI), p 5 0.004. Conclusion: Even among children with relatively better preserved thymus compared to adults, those with more rapid thymic recovery leading to more robust rise in RTE will have superior clinical outcome. These findings should spur further research aiming to enhance recovery of the central, thymic derived pathway of T cell generation. Background: We demonstrated that T cells from GBM patients engineered to express a HER2-specific chimeric antigen receptor (CAR) kill autologous HER2 + GBM cells ex vivo, including the CD133 + GBM stem cell population. In vivo, the adoptive transfer of HER2-specific T cells resulted in regression of established GBM in the brain of mice, yet tumors recurred in a number of treated animals. This limitation in T-cell efficacy is most likely due to a) limited T-cell persistence in vivo and/or b) tumor antigen loss variants in treated tumors. Since the majority of GBMs are positive for CMVpp65 we expressed HER2.CARs in CMV-specific cytotoxic T cells (CTLs) to a) enhance their persistence in vivo following native T-cell receptor (abTCR) engagement with CMVantigens and b) improve their antitumor activity by simultaneously targeting CMV and HER2. Methods: To study the feasibility of generating CMV CTLs from GBM patients, we determined the precursor frequency of CMV-specific T cells in 12 patients using IFN-g ELIspot assays. To generate CMV CTL ex vivo, peripheral blood mononuclear cells were transduced with an adenovirus vector; encoding the immunodominant CMV-pp65 antigen (Ad5f35pp65) then stimulated with autologous EBV transformed Ad5f35pp65-transduced irradiated lymphoblastic cell lines (EBV-LCL). CTLs were then transduced with a retroviral vector encoding a HER2.CAR (FRP5.CD28.z). We detected the expression of the CAR transgene using flowcytometry. To concomitantly identify the CMV-specific T cell population we used pentamer analysis for CMVpp65. We performed 51 Cr-release assays to characterize the functionality of HER2.CAR CMV.CTLs ex vivo. Results: CMV-specific T cells were readily detectable in the blood of GBM patients as judged by IFN-g secretion after stimulation with CMVpp65 PepMixesÔ. We were able to generate CTLs that are specific for CMV through their endogenous ab TCR and specific for HER2 through the CAR. Approximately 50% of CMVpp65-specific CTLs expressed HER2.CARs on the cell surface. CMV-specific CTLs expressing the HER2-specific CAR recognized and killed the HER2-positive GBM cell line (U373) as well as autologous OKT3-blasted T cells pulsed with CMVpp65 Pep-MixesÔ in a standard 4 hour 51 Cr-release assays. Neither the HER2 -ve cell lines nor autologous OKT3-blasted T cells were killed. Conclusion: Our data demonstrates the feasibility of generating CAR expressing CMVpp65-specific CTLs that are functional against HER2 and CMV expressed in GBM. Pediatric patients with high risk Ewing's family tumors (hrEFT), relapsed or metastatic at diagnosis, have very poor outcome with conventional chemotherapy. A steep dose-response curve to alkylating agents suggests myeloablative chemotherapy as a potential therapeutic modality, but controversy persists, warranting additional investigation. We retrospectively reviewed hrEFT patients treated with conventional therapy (CHEMO) in comparison to high dose alkylator-based chemotherapy and autologous stem cell transplantation (ASCT) treated at a single center. Thirty-six patients were assigned into 4 groups based on disease features and therapy received: REL/CHEMO (n 5 12), REL/ ASCT (n 5 5), MET/CHEMO (n 5 14), MET/ASCT (n 5 5). Kaplan-Meier estimator was used to compare event free survival (EFS) and overall survival (OS). Seven of 10 ASCT patients received busulfan, melphalan, thiotepa and 3 of 10 received melphalan, carboplatin and etoposide prior to autologous peripheral blood stem cell rescue. Both regimens included the chemoprotectant amifostine. Patients had complete response (CR), very good partial response (VGPR) or partial disease response (PR) at the time of ASCT. REL/CHEMO patients received a variety of salvage non-high dose chemotherapies. EFS at 1 and 3 years from 1 st relapse were 100% and 53% in REL/ASCT group in comparison to 25% and 8% respectively in REL/CHEMO group (p 5 0.0007). OS at 1 and 3 years from diagnosis were 100% and 80% for REL/ASCT group and 92% and 42% respectively in REL/CHEMO group (p 5 0.013). ASCT-related toxicities were febrile neutropenia and grade 3 mucositis (n 5 10), adrenal insufficiency (n 5 4), bacteriemia (n 5 1), and herpes zoster reactivation (n 5 3). We did not observe any veno-occlusive disease of liver (VOD) or graft failure. There were no regimen-related mortalities. Four of 5 patients are surviving in the REL/ASCT group, and all are currently disease-free (one after a further relapse) with a median time from 1 st relapse of 3.3 years (range 1.7-8.9). In comparison, none of the 12 children with relapsed disease treated with chemotherapy alone are surviving, with median time from relapse to death of 1 year (range 0.1-4.8). In patients with metastatic disease at diagnosis, the 1-year OS was 75% in MET/ASCT group, and 64% respectively in MET/CHEMO group (p 5 0.79). Our data suggest ASCT is tolerable and should be considered as therapeutic option for relapsed patients. Randomized studies are required to support these observations.
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STEM CELL BIOLOGY 85 SYSTEMIC ADMINISTRATION OF PLEIOTROPHIN INDUCES HEMATOPOI-ETIC STEM CELL (HSC) REGENERATION IN VIVO
Himburg, H.A., Daher, P., Meadows, S.K., Russell, J.L., Doan, P., Chao, N.J., Chute, J.P. Duke University, Durham, NC The elucidation of bone marrow microenvironmental signals which promote HSC regeneration in vivo would have important implications for the treatment of patients undergoing radiation therapy, chemotherapy and stem cell transplantation. We recently reported that pleiotrophin, a soluble heparin-binding growth factor, induced a 10-fold expansion of long-term repopulating HSCs in culture (Himburg et al. Blood, Nov 2008; 112: 78) . Based on this observation, we hypothesized that PTN might also be a regenerative growth factor for HSCs. Here we tested the effect of systemic administration of PTN to mice to determine if PTN could promote HSC regeneration in vivo following total body irradiation (TBI). C57Bl6 mice were irradiated with 700 cGy followed by
